Here, we summarize clinical associations between elevated SAA levels and major cardiometabolic conditions—including obesity, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), and hypertension—and discuss potential mechanisms based on preclinical studies. Here, SAA1 is linked to metabolic dysfunction-associated steatotic liver disease.